A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

NCT07282353 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

135

Enrollment

OTHER

Sponsor class

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: 2mg CS0159
DRUG: Placebo

Sponsor

Cascade Pharmaceuticals, Inc